A Ph2b to Evaluate Clinical Efficacy and Safety of Tildacerfont in Adult CAH
Study sponsor: Spruce Biosciences
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2024-02-09Actual
Enrollment · participants96Actual
Source updated2025-07-08Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.